ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data
argenx SE’s U.S. shares inched up Wednesday, trailing the biotech sector after Immunovant released rheumatoid-arthritis data that drew new focus to the same drug class as argenx’s VYVGART franchise. ARGX was trading at $803.67 near the end of the session, up 0.7%. The iShares Nasdaq Biotechnology ETF added 2.1% and SPDR S&P Biotech ETF climbed 3.8%. Shares of Immunovant soared 35.1%. Roivant Sciences, Immunovant’s parent, rose 14.6%, according to market data.